BIOLASE, INC: Nasdaq/NYSE listing notice — BIOLASE receives Nasdaq bid price deficiency notice; 180 days to cure

BIOLASE, INC

Common stock closed below $1.00 per share for 30 consecutive business days through Jan 10, 2023.
Company has 180 calendar days, until July 10, 2023, to regain compliance under Nasdaq Listing Rule 5550(a)(2).
To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days before Compliance Date.
If not cured, may seek additional 180-day period by providing intent to cure, potentially via reverse stock split.
Company intends to monitor closing bid price and consider available options to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BIOLASE, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 11, 2023, BIOLASE, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, ending on January 10, 2023, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or u

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-006843

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.